Fascaplysin
Based on 1 Customer Validation
Fascaplysin is an antimicrobial and cytotoxic red pigment, that can come from the marine sponge (Fascaplysinopsis sp.). Fascaplysin has been synthesized in seven steps from indole (65% yield). Fascaplysin can induces apoptosis and autophagy in human leukemia HL-60 cells. Fascaplysin shows anti-tumor activity.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 95.64%
- CAS. Nr.: 114719-57-2
- Formel: C18H11ClN2O
- Molecular Weight:306.75
-
Speicherung:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biologische Aktivität
Beschreibung
IC50 & Target
|
CDK4 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 786-0 | IC50 |
6.7 μM
Compound: 1, NSC-622398
|
Antitumor activity against human 786-O cells
Antitumor activity against human 786-O cells
|
[PMID: 15165138] |
| A498 | IC50 |
5.2 μM
Compound: 1, NSC-622398
|
Antitumor activity against human A498 cells
Antitumor activity against human A498 cells
|
[PMID: 15165138] |
| A549 | IC50 |
0.69 μM
Compound: 2
|
Growth inhibition of p53+, pRb+ human A549 cells after 48 hrs by MTT assay
Growth inhibition of p53+, pRb+ human A549 cells after 48 hrs by MTT assay
|
[PMID: 25368960] |
| A549 | IC50 |
4.2 μM
Compound: 1, NSC-622398
|
Antitumor activity against human A549/ATCC cells
Antitumor activity against human A549/ATCC cells
|
[PMID: 15165138] |
| ACHN | IC50 |
>10 μM
Compound: 1, NSC-622398
|
Antitumor activity against human ACHN cells
Antitumor activity against human ACHN cells
|
[PMID: 15165138] |
| BT-549 | IC50 |
>10 μM
Compound: 1, NSC-622398
|
Antitumor activity against human BT549 cells
Antitumor activity against human BT549 cells
|
[PMID: 15165138] |
| CAKI-1 | IC50 |
6.1 μM
Compound: 1, NSC-622398
|
Antitumor activity against human Caki1 cells
Antitumor activity against human Caki1 cells
|
[PMID: 15165138] |
| Calu-1 | IC50 |
1.3 μM
Compound: 2
|
Growth inhibition of p53 null, pRb+ human Calu1 cells after 48 hrs by MTT assay
Growth inhibition of p53 null, pRb+ human Calu1 cells after 48 hrs by MTT assay
|
[PMID: 25368960] |
| CCRF-CEM | IC50 |
>10 μM
Compound: 1, NSC-622398
|
Antitumor activity against human CCRF-CEM cells
Antitumor activity against human CCRF-CEM cells
|
[PMID: 15165138] |
| COLO 205 | IC50 |
1.2 μM
Compound: 1, NSC-622398
|
Antitumor activity against human COLO205 cells
Antitumor activity against human COLO205 cells
|
[PMID: 15165138] |
| DU-145 | IC50 |
4.9 μM
Compound: 1, NSC-622398
|
Antitumor activity against human DU145 cells
Antitumor activity against human DU145 cells
|
[PMID: 15165138] |
| EKVX | IC50 |
5.1 μM
Compound: 1, NSC-622398
|
Antitumor activity against human EKVX cells
Antitumor activity against human EKVX cells
|
[PMID: 15165138] |
| HCC 2998 | IC50 |
1.7 μM
Compound: 1, NSC-622398
|
Antitumor activity against human HCC2998 cells
Antitumor activity against human HCC2998 cells
|
[PMID: 15165138] |
| HCT-116 | IC50 |
0.6 μM
Compound: 1, NSC-622398
|
Antitumor activity against human HCT116 cells
Antitumor activity against human HCT116 cells
|
[PMID: 15165138] |
| HCT-15 | IC50 |
>10 μM
Compound: 1, NSC-622398
|
Antitumor activity against human HCT15 cells
Antitumor activity against human HCT15 cells
|
[PMID: 15165138] |
| HL-60(TB) | IC50 |
>10 μM
Compound: 1, NSC-622398
|
Antitumor activity against human HL-60(TB) cells
Antitumor activity against human HL-60(TB) cells
|
[PMID: 15165138] |
| HOP-62 | IC50 |
4.7 μM
Compound: 1, NSC-622398
|
Antitumor activity against human HOP62 cells
Antitumor activity against human HOP62 cells
|
[PMID: 15165138] |
| Hs-578T | IC50 |
>10 μM
Compound: 1, NSC-622398
|
Antitumor activity against human Hs 578T cells
Antitumor activity against human Hs 578T cells
|
[PMID: 15165138] |
| HT-29 | IC50 |
>10 μM
Compound: 1, NSC-622398
|
Antitumor activity against human HT-29 cells
Antitumor activity against human HT-29 cells
|
[PMID: 15165138] |
| Huh-7 | CC50 |
0.589 μM
Compound: GNF-Pf-1458
|
NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)
NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)
|
[PMID: 18579783] |
| IGROV-1 | IC50 |
4.5 μM
Compound: 1, NSC-622398
|
Antitumor activity against human IGROV1 cells
Antitumor activity against human IGROV1 cells
|
[PMID: 15165138] |
| K562 | IC50 |
>10 μM
Compound: 1, NSC-622398
|
Antitumor activity against human K562 cells
Antitumor activity against human K562 cells
|
[PMID: 15165138] |
| KM12 | IC50 |
4.6 μM
Compound: 1, NSC-622398
|
Antitumor activity against human KM12 cells
Antitumor activity against human KM12 cells
|
[PMID: 15165138] |
| LOX IMVI | IC50 |
>10 μM
Compound: 1, NSC-622398
|
Antitumor activity against human LOXIMVI cells
Antitumor activity against human LOXIMVI cells
|
[PMID: 15165138] |
| LS174T | IC50 |
0.88 μM
Compound: 2
|
Growth inhibition of p53+, pRb+ human LS 174T cells after 48 hrs by MTT assay
Growth inhibition of p53+, pRb+ human LS 174T cells after 48 hrs by MTT assay
|
[PMID: 25368960] |
| M14 | IC50 |
0.92 μM
Compound: 1, NSC-622398
|
Antitumor activity against human M14 cells
Antitumor activity against human M14 cells
|
[PMID: 15165138] |
| Malme-3M | IC50 |
0.36 μM
Compound: 1, NSC-622398
|
Antitumor activity against human MALME-3M cells
Antitumor activity against human MALME-3M cells
|
[PMID: 15165138] |
| MCF7 | IC50 |
>10 μM
Compound: 1, NSC-622398
|
Antitumor activity against ADF-resistant human MCF7 cells
Antitumor activity against ADF-resistant human MCF7 cells
|
[PMID: 15165138] |
| MCF7 | IC50 |
>10 μM
Compound: 1, NSC-622398
|
Antitumor activity against human MCF7 cells
Antitumor activity against human MCF7 cells
|
[PMID: 15165138] |
| MDA-MB-231 | IC50 |
>10 μM
Compound: 1, NSC-622398
|
Antitumor activity against human MDA-MB-231 cells
Antitumor activity against human MDA-MB-231 cells
|
[PMID: 15165138] |
| MDA-MB-435 | IC50 |
0.56 μM
Compound: 1, NSC-622398
|
Antitumor activity against human MDA-MB-435 cells
Antitumor activity against human MDA-MB-435 cells
|
[PMID: 15165138] |
| MDA-N | IC50 |
0.56 μM
Compound: 1, NSC-622398
|
Antitumor activity against human MDA-N cells
Antitumor activity against human MDA-N cells
|
[PMID: 15165138] |
| MOLT-4 | IC50 |
>10 μM
Compound: 1, NSC-622398
|
Antitumor activity against human MOLT4 cells
Antitumor activity against human MOLT4 cells
|
[PMID: 15165138] |
| NCI-H226 | IC50 |
9.6 μM
Compound: 1, NSC-622398
|
Antitumor activity against human NCI-H226 cells
Antitumor activity against human NCI-H226 cells
|
[PMID: 15165138] |
| NCI-H23 | IC50 |
4.5 μM
Compound: 1, NSC-622398
|
Antitumor activity against human NCI-H23 cells
Antitumor activity against human NCI-H23 cells
|
[PMID: 15165138] |
| NCI-H322M | IC50 |
5 μM
Compound: 1, NSC-622398
|
Antitumor activity against human NCI-H322M cells
Antitumor activity against human NCI-H322M cells
|
[PMID: 15165138] |
| NCI-H460 | IC50 |
4.2 μM
Compound: 1, NSC-622398
|
Antitumor activity against human NCI-H460 cells
Antitumor activity against human NCI-H460 cells
|
[PMID: 15165138] |
| NCI-H522 | IC50 |
4.5 μM
Compound: 1, NSC-622398
|
Antitumor activity against human NCI-H522 cells
Antitumor activity against human NCI-H522 cells
|
[PMID: 15165138] |
| OVCAR-3 | IC50 |
1.5 μM
Compound: 1, NSC-622398
|
Antitumor activity against human OVCAR-3 cells
Antitumor activity against human OVCAR-3 cells
|
[PMID: 15165138] |
| OVCAR-4 | IC50 |
5.3 μM
Compound: 1, NSC-622398
|
Antitumor activity against human OVCAR4 cells
Antitumor activity against human OVCAR4 cells
|
[PMID: 15165138] |
| OVCAR-5 | IC50 |
4.4 μM
Compound: 1, NSC-622398
|
Antitumor activity against human OVCAR5 cells
Antitumor activity against human OVCAR5 cells
|
[PMID: 15165138] |
| OVCAR-8 | IC50 |
>10 μM
Compound: 1, NSC-622398
|
Antitumor activity against human OVCAR8 cells
Antitumor activity against human OVCAR8 cells
|
[PMID: 15165138] |
| PC-3 | IC50 |
>10 μM
Compound: 1, NSC-622398
|
Antitumor activity against human PC3 cells
Antitumor activity against human PC3 cells
|
[PMID: 15165138] |
| PC-3 | IC50 |
0.92 μM
Compound: 2
|
Growth inhibition of p53 null,pRb+ human PC3 cells after 48 hrs by MTT assay
Growth inhibition of p53 null,pRb+ human PC3 cells after 48 hrs by MTT assay
|
[PMID: 25368960] |
| RPMI-8226 | IC50 |
>10 μM
Compound: 1, NSC-622398
|
Antitumor activity against human RPMI8226 cells
Antitumor activity against human RPMI8226 cells
|
[PMID: 15165138] |
| RXF 393 | IC50 |
3.5 μM
Compound: 1, NSC-622398
|
Antitumor activity against human RXF393 cells
Antitumor activity against human RXF393 cells
|
[PMID: 15165138] |
| SF-268 | IC50 |
>10 μM
Compound: 1, NSC-622398
|
Antitumor activity against human SF268 cells
Antitumor activity against human SF268 cells
|
[PMID: 15165138] |
| SF-295 | IC50 |
3.9 μM
Compound: 1, NSC-622398
|
Antitumor activity against human SF295 cells
Antitumor activity against human SF295 cells
|
[PMID: 15165138] |
| SF-539 | IC50 |
4.2 μM
Compound: 1, NSC-622398
|
Antitumor activity against human SF539 cells
Antitumor activity against human SF539 cells
|
[PMID: 15165138] |
| Sf9 | IC50 |
0.35 μM
Compound: Fascaplysin
|
Inhibition of CDK4/Cyclin D (unknown origin) expressed in baculovirus infected insect Sf9 cells using human pRB as substrate in presence of [gamma-32P]ATP
Inhibition of CDK4/Cyclin D (unknown origin) expressed in baculovirus infected insect Sf9 cells using human pRB as substrate in presence of [gamma-32P]ATP
|
[PMID: 26741853] |
| Sf9 | IC50 |
0.55 μM
Compound: 4
|
Inhibition of human CDK4/ Cyclin D1 catalytic subunit expressed in Sf9 insect cells assessed as GST-RB152 fusion protein phosphorylation-associated depletion in ATP level by luminescence assay
Inhibition of human CDK4/ Cyclin D1 catalytic subunit expressed in Sf9 insect cells assessed as GST-RB152 fusion protein phosphorylation-associated depletion in ATP level by luminescence assay
|
[PMID: 19632122] |
| Sf9 | IC50 |
0.55 μM
Compound: 1
|
Inhibition of human CDK4/GST-cyclin D1 expressed in Sf9 cells assessed as retinoblastoma GST-RB152 phosphorylation
Inhibition of human CDK4/GST-cyclin D1 expressed in Sf9 cells assessed as retinoblastoma GST-RB152 phosphorylation
|
[PMID: 18650093] |
| Sf9 | IC50 |
500 μM
Compound: 4
|
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay
|
[PMID: 19632122] |
| Sf9 | IC50 |
500 μM
Compound: 1
|
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation
|
[PMID: 18650093] |
| SK-MEL-28 | IC50 |
9.3 μM
Compound: 1, NSC-622398
|
Antitumor activity against human SK-MEL-28 cells
Antitumor activity against human SK-MEL-28 cells
|
[PMID: 15165138] |
| SK-MEL-5 | IC50 |
2 μM
Compound: 1, NSC-622398
|
Antitumor activity against human SK-MEL-5 cells
Antitumor activity against human SK-MEL-5 cells
|
[PMID: 15165138] |
| SK-OV-3 | IC50 |
>10 μM
Compound: 1, NSC-622398
|
Antitumor activity against human SKOV3 cells
Antitumor activity against human SKOV3 cells
|
[PMID: 15165138] |
| SN12C | IC50 |
4.2 μM
Compound: 1, NSC-622398
|
Antitumor activity against human SN12C cells
Antitumor activity against human SN12C cells
|
[PMID: 15165138] |
| SNB-19 | IC50 |
6.1 μM
Compound: 1, NSC-622398
|
Antitumor activity against human SNB19 cells
Antitumor activity against human SNB19 cells
|
[PMID: 15165138] |
| SNB-75 | IC50 |
5.4 μM
Compound: 1, NSC-622398
|
Antitumor activity against human SNB75 cells
Antitumor activity against human SNB75 cells
|
[PMID: 15165138] |
| SR | IC50 |
>10 μM
Compound: 1, NSC-622398
|
Antitumor activity against human SR cells
Antitumor activity against human SR cells
|
[PMID: 15165138] |
| SW-620 | IC50 |
3.7 μM
Compound: 1, NSC-622398
|
Antitumor activity against human SW620 cells
Antitumor activity against human SW620 cells
|
[PMID: 15165138] |
| T47D | IC50 |
>10 μM
Compound: 1, NSC-622398
|
Antitumor activity against human T47D cells
Antitumor activity against human T47D cells
|
[PMID: 15165138] |
| TK-10 | IC50 |
5.4 μM
Compound: 1, NSC-622398
|
Antitumor activity against human TK10 cells
Antitumor activity against human TK10 cells
|
[PMID: 15165138] |
| U-251 | IC50 |
3.6 μM
Compound: 1, NSC-622398
|
Antitumor activity against human U251 cells
Antitumor activity against human U251 cells
|
[PMID: 15165138] |
| UACC-257 | IC50 |
>10 μM
Compound: 1, NSC-622398
|
Antitumor activity against human UACC257 cells
Antitumor activity against human UACC257 cells
|
[PMID: 15165138] |
| UACC-62 | IC50 |
4.9 μM
Compound: 1, NSC-622398
|
Antitumor activity against human UACC62 cells
Antitumor activity against human UACC62 cells
|
[PMID: 15165138] |
| UO-31 | IC50 |
>10 μM
Compound: 1, NSC-622398
|
Antitumor activity against human UO31 cells
Antitumor activity against human UO31 cells
|
[PMID: 15165138] |
In Vitro
Fascaplysin induces autophagy as a cytoprotective response via ROS and p8 in vascular endothelial cells (VECs)[2].
Fascaplysin targets metabolic activity of the prostate cancer cells, without disrupting cell membrane's integrity[2].
.
Fascaplysin induces caspase mediated crosstalk between apoptosis and autophagy through the inhibition of PI3K/AKT/mTOR signaling cascade in human leukemia HL-60 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Chemical Information
-
CAS. Nr. 114719-57-2
-
Appearance Solid
-
Molecular Weight 306.75
-
Formel C18H11ClN2O
-
Color Brown to dark brown
-
SMILES
O=C1C2=C3NC4=C(C=CC=C4)C3=CC=[N+]2C5=C1C=CC=C5.[Cl-]
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 16 mg/mL (52.16 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Reinheit & Dokumentation
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2600 mL | 16.2999 mL | 32.5998 mL | 81.4996 mL |
| 5 mM | 0.6520 mL | 3.2600 mL | 6.5200 mL | 16.2999 mL | |
| 10 mM | 0.3260 mL | 1.6300 mL | 3.2600 mL | 8.1500 mL | |
| 15 mM | 0.2173 mL | 1.0867 mL | 2.1733 mL | 5.4333 mL | |
| 20 mM | 0.1630 mL | 0.8150 mL | 1.6300 mL | 4.0750 mL | |
| 25 mM | 0.1304 mL | 0.6520 mL | 1.3040 mL | 3.2600 mL | |
| 30 mM | 0.1087 mL | 0.5433 mL | 1.0867 mL | 2.7167 mL | |
| 40 mM | 0.0815 mL | 0.4075 mL | 0.8150 mL | 2.0375 mL | |
| 50 mM | 0.0652 mL | 0.3260 mL | 0.6520 mL | 1.6300 mL |